Johnson & Johnson (JNJ)
J&J Wins FDA Nod for Subcutaneous Version of NSCLC Drug Rybrevant
JNJ wins FDA approval for a subcutaneous version of Rybrevant, cutting treatment time to minutes and boosting convenience across NSCLC indications.
Johnson & Johnson: Valuation Premium Justified By Accelerating Growth And Mix Premiumization
Johnson & Johnson is rated a buy, with accelerating revenue and earnings growth driven by TREMFYA, CARVYKTI, and robust MedTech innovation. JNJ's portfolio reshaping (divesting Orthopaedics and focusing on premium cardiovascular and vision franchises) should enhance margins and long-term growth prospects. TREMFYA's rapid adoption in IBD and the anticipated 2026 launch of icotrokinra position JNJ for continued immunology growth despite STELARA's LOE.
Is Trending Stock Johnson & Johnson (JNJ) a Buy Now?
Zacks.com users have recently been watching Johnson & Johnson (JNJ) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Final Trade: JNJ, NVO, UBER, BMY
The final trades of the day with CNBC's Melissa Lee and the 'Fast Money' traders.
FDA Approves J&J's Akeega for Expanded Use in Prostate Cancer
JNJ secures FDA approval to expand Akeega into earlier-stage prostate cancer, backed by strong phase III data and a first-of-its-kind precision combo.
Johnson & Johnson (JNJ) Is Considered a Good Investment by Brokers: Is That True?
Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a stock. While media reports about rating changes by these brokerage-firm employed (or sell-side) analysts often affect a stock's price, do they really matter?
Jury orders Johnson & Johnson to pay $40 million to two women in latest talc trial
A California jury on Friday awarded $40 million to two women who said Johnson & Johnson's baby powder was to blame for their ovarian cancer.
Johnson & Johnson: Reliable Cash Flows, Moderate Expectations
Johnson & Johnson has surged 14% since my last update, surpassing my $188 target, and now trades near $200. Top-line growth is accelerating, but revenue expansion remains below industry rates and is partially priced in after a strong rally. JNJ's capital structure remains leveraged, clouding its outlook despite progress in positioning for future success.
Johnson & Johnson (JNJ) Exceeds Market Returns: Some Facts to Consider
In the most recent trading session, Johnson & Johnson (JNJ) closed at $210.01, indicating a +1.68% shift from the previous trading day.
5 Dividend Powerhouses That Belong in Every Retirement Portfolio Right Now
For investors approaching or in retirement, the right stock portfolio balances reliable income, low volatility, and consistent dividend growth.
JNJ vs. PFE: Which Blue-Chip Drug Stock is the Better Investment Now?
JNJ and PFE battle patent cliffs and policy headwinds, but rising estimates and stronger 2025 momentum push JNJ ahead in this blue-chip faceoff.
3 Under-the-Radar Dividend Stocks Quietly Beating the Market
For reasons that seem pretty obvious, dividend investors tend to chase the most familiar names like Pepsi (NYSE:PEP), Johnson and Johnson (NYSE:JNJ), and Procter & Gamble (NYSE:PG), and they do so for a lot of the right reasons.
